[1]张书林,黄盛源,刘忠林,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较[J].医学信息,2021,34(24):141-143.[doi:10.3969/j.issn.1006-1959.2021.24.036]
　ZHANG Shu-lin,HUANG Sheng-yuan,LIU Zhong-lin,et al.Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma[J].Medical Information,2021,34(24):141-143.[doi:10.3969/j.issn.1006-1959.2021.24.036]
点击复制

吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年24期
页码:
141-143
栏目:
药物与临床
出版日期:
2021-12-15

文章信息/Info

Title:
Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma
文章编号:
1006-1959（2021）24-0141-03
作者:
张书林; 黄盛源; 刘忠林; 等
（兴国县中医院内一科，江西 兴国 342400）
Author(s):
ZHANG Shu-lin; HUANG Sheng-yuan; LIU Zhong-lin; et al.
(Department of Internal Medicine,Xingguo Hospital of Traditional Chinese Medicine,Xingguo 342400,Jiangxi,China)
关键词:
吉西他滨; 多西他赛; 顺铂; 非小细胞肺鳞癌
Keywords:
Gemcitabine; Docetaxel; Cisplatin; Non-small cell lung squamous cell carcinoma
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2021.24.036
文献标志码:
A
摘要:
目的 观察吉西他滨和多西他赛联合顺铂对晚期非小细胞肺鳞癌的效果。方法 选取2019年6月-2021年5月在我院诊治的62例晚期非小细胞肺鳞癌患者为研究对象，采用随机数字表法分为对照组和观察组，各31例。对照组采用多西他赛联合顺铂治疗，观察组采用吉西他滨联合顺铂治疗，比较两组临床治疗总有效率、不良反应发生率、生活质量评分、T淋巴细胞功能指标。结果 观察组治疗总有效率为58.06%，与对照组的54.84%比较，差异无统计学意义（P＞0.05）；观察组乏力、脱发、血小板减少、白细胞减少、粒细胞减少发生率均小于对照组（P＜0.05）；两组生活质量评分均低于治疗前，但观察组高于对照组（P＜0.05）；两组 CD3+、CD4+均低于治疗前，但观察组高于对照组（P＜0.05）。结论 吉西他滨和多西他赛联合顺铂对晚期非小细胞肺鳞癌临床效果基本一致，但是吉西他滨联合顺铂治疗临床不良反应少，患者生活质量评分高，且对T淋巴细胞亚群影响小，相对具有更优的应用优势。
Abstract:
Objective To observe the effect of gemcitabine and docetaxel combined with cisplatin on advanced non-small cell lung squamous cell carcinoma.Methods A total of 62 patients with advanced non-small cell lung squamous cell carcinoma treated in our hospital from June 2019 to May 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 31 cases in each group. The control group was treated with docetaxel combined with cisplatin, and the observation group was treated with gemcitabine combined with cisplatin. The total effective rate, incidence of adverse reactions, quality of life score and T lymphocyte function indexes of the two groups were compared.Results The total effective rate of the observation group was 58.06%, which was compared with 54.84% of the control group, the difference was not statistically significant (P>0.05). The incidence of fatigue, alopecia, thrombocytopenia, leukopenia and neutropenia in the observation group were lower than those in the control group (P<0.05).The quality of life scores of the two groups were lower than those before treatment, but the observation group was higher than the control group (P<0.05). CD3+ and CD4+ in the two groups were lower than those before treatment, but the observation group was higher than the control group (P<0.05).Conclusion The clinical effects of gemcitabine and docetaxel combined with cisplatin in the treatment of advanced non-small cell lung squamous cell carcinoma are basically the same. However, gemcitabine combined with cisplatin has less clinical adverse reactions, higher quality of life scores, and less influence on T lymphocyte subsets, which has relatively better application advantages.

参考文献/References:

[1]别良玉,李敏,陈贝贝,等.晚期非小细胞肺癌3种EGFR-TKI治疗的临床疗效及药物经济学分析[J].肿瘤基础与临床,2016,29(2):143-146.[2]麦泽锋.乌苯美司联合紫杉醇与顺铂方案治疗晚期非小细胞肺癌的临床疗效及对免疫功能的影响[J].中国老年学杂志,2016,36(15):3731-3733.[3]柯传庆,彭恩兰,彭秋平,等.晚期非小细胞肺癌维持治疗探讨[J].肿瘤基础与临床,2017,30(2):181-184.[4]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2020[J].CA Cancer J Clin,2020,70(1):7-30.[5]李显桃.吉西他滨和多西他赛联合顺铂对晚期非小细胞肺癌的效果对比[J].当代医学,2018,24(1):125-127.[6]芮晓艳,孙沫,丁婷婷,等.吉西他滨联合顺铂对晚期非小细胞肺癌的临床疗效观察[J].实用癌症杂志,2018,33(5):811-813.[7]徐寿华,周冬霞,杜海燕.盐酸埃克替尼治疗晚期非小细胞肺癌患者的疗效观察[J].中国肿瘤临床与康复,2020,27(5):568-571.[8]丁淑云,张晋萍,梁勇,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺癌的近期疗效及安全性分析[J].中国药物经济学,2017,12(11):33-36.[9]黄潇,黄敏,李筱瑜,等.吉西他滨单药与联合顺铂化疗治疗中老年晚期非小细胞肺癌的疗效观察[J].现代肿瘤医学,2017,25(19):3079-3081.[10]符琳琳,张娟.吉西他滨和顺铂联合化疗对中老年晚期非小细胞肺癌的疗效观察[J].中国医刊,2017,52(7):34-37.[11]Cao M,Chen W.Epidemiology of lung cancer in China[J].Thorac Cancer,2019,10(1):3-7.[12]姜红波.培美曲塞联合顺铂治疗非小细胞肺癌的临床疗效评价[J].中国现代药物应用,2019,13(1):96-97.[13]薛英杰,贾靖,吴杨,等.吉西他滨与培美曲塞分别联合顺铂治疗非小细胞肺癌的临床效果[J].解放军医药杂志,2018,30(12):11-14.[14]甘霞,钟明艳,刘波.培美曲塞二钠联合顺铂治疗晚期非鳞非小细胞肺癌的临床疗效及安全性[J].临床合理用药杂志,2018(36):61-62.[15]李长生,任中海.培美曲塞联合顺铂一线治疗晚期肺腺癌疗效及安全性分析[J].中华肿瘤防治杂志,2016,23(18):1250-1253.[16]徐炎良,陈春香.化疗对晚期非小细胞肺癌患者表皮生长因子受体基因突变状态的影响[J].实用癌症杂志,2017,32(3):386-388.[17]Sequist LV,Rolfe L,Allen AR.Rociletinibin EGFR-Mutated Non-Small Cell Lung Cancer[J].N Engl J Med,2015,373(6):578-579.[18]黄慧,陈滔.培美曲塞联合顺铂对晚期非鳞非小细胞肺癌患者血清肿瘤标志物的影响[J].药物评价研究,2018,41(12):2289-2293.[19]张艳艳.吉西他滨联合顺铂治疗晚期非小细胞肺癌患者的疗效及其对外周血T淋巴细胞亚群的影响[J].肿瘤基础与临床,2018,31(2):60-62.[20]周言志.吉西他滨联合顺铂对晚期非小细胞肺癌的效果分析[J].中国医药指南,2020,18(5):40.

相似文献/References:

[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
　PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2018,31(24):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[2]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(24):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[3]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
　ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Medical Information,2018,31(24):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[4]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
　LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(24):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[5]张伟娜,黄晓华.多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价[J].医学信息,2019,32(08):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
　ZHANG Wei-na,HUANG Xiao-hua.Clinical Evaluation of Docetaxel Combined with Lobaplatin in the Treatment of Patients with Advanced Ovarian Cancer[J].Medical Information,2019,32(24):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
[6]刘 鑫,张劲松,王海峰.转移性激素敏感性前列腺癌研究进展[J].医学信息,2019,32(15):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
　LIU Xin,ZHANG Jin-song,WANG Hai-feng.Research Progress on the Metastatic Hormone-sensitive Prostate Cancer[J].Medical Information,2019,32(24):30.[doi:10.3969/j.issn.1006-1959.2019.15.011]
[7]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2020,33(24):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
[8]杨 欢,朱 梅,张改琴,等.多西他赛腹腔灌注加静脉化疗及口服替吉奥联合阿帕替尼治疗胃癌腹膜转移患者的效果[J].医学信息,2022,35(19):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
　YANG Huan,ZHU Mei,ZHANG Gai-qin,et al.Effect of Docetaxel Intraperitoneal Perfusion Plus Intravenous Chemotherapy and Oral Tegafur Combined with Apatinib in the Treatment of Gastric Cancer Patients with Peritoneal Metastasis[J].Medical Information,2022,35(24):121.[doi:10.3969/j.issn.1006-1959.2022.19.034]
[9]王启平,兰安宁,吴晓峰.低剂量地塞米松对乳腺癌化疗不良反应的影响[J].医学信息,2020,33(14):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
　WANG Qi-ping,LAN An-ning,WU Xiao-feng.Effect of Low-dose Dexamethasone on Adverse Reactions of Chemotherapy in Breast Cancer[J].Medical Information,2020,33(24):146.[doi:10.3969/j.issn.1006-1959.2020.14.045]
[10]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(24):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]

更新日期/Last Update: 1900-01-01